The diminished stereoselectivity is attributed to a change of
exclusive catalyst control to competing chiral substrate control.
In addition, the catalyst loading could be reduced to only
2 mol% without deterioration in the selectivity obtained
(Table 2, entries 1 and 2). Using these optimized conditions,
the allylic alkylation of 4 was performed using different
Grignard reagents with high selectivities in all cases
(Table 2). Again, when (+)-taniaphos was used as the ligand,
the anti isomers were obtained selectively (entries 1, 3, 5 and 7).
The (ꢁ)-enantiomer of the ligand was slightly less selective,
but led to the syn product with very high ratios (entries 2, 4, 6
and 8) and in all cases the minor isomer could be readily
removed by column chromatography. An important feature is
that the reaction is readily scalable to 5 mmol with similar
results as shown for entries 4 and 7. Noteworthily, the reaction
also provided the anti isomer with total selectivity when
a cyclic Grignard reagent was used in combination with
(+)-taniaphos (entry 9). However, when (ꢁ)-taniaphos was
used with this Grignard reagent, a strong mismatch effect was
observed and the products were obtained in a 20 : 20 : 60
syn : anti : linear ratio. PhMgBr was also used but in this case
no reaction was observed at ꢁ80 1C and the starting material
was recovered.
additional proof of the versatility of this methodology, we
applied this synthetic route to compound anti-5d and obtained
g-hexyl substituted a,b-unsaturated d-lactone 8b in a comparable
yield (Scheme 4b). These examples show that this new methodo-
logy gives access to cis and trans disubstituted d-lactones
with total stereocontrol and with the possibility of introducing
different alkyl groups at the g-position in a general fashion.
In summary, we have described a stereoselective synthesis of
syn and anti 1,2-hydroxyalkyl structures based on a copper-
catalyzed asymmetric allylic alkylation of d-alkoxy-substituted
allylic bromides with Grignard reagents. The use of a dioxolane-
containing allylic bromide is crucial for the regiochemistry
while the syn–anti stereochemistry of the product can be tuned
using the appropriate enantiomer of the chiral catalyst.
Financial support from The Netherlands Organization for
Scientific Research (NWO-CW) is acknowledged. M.F.-M. is
grateful to the Spanish Ministry of Science and Innovation
(MICINN) for a postdoctoral grant.
Notes and references
1 (a) K.-S. Yeung and I. Paterson, Chem. Rev., 2005, 105, 4237;
(b) B. Schetter and R. Mahrwald, Angew. Chem., Int. Ed., 2006, 45,
7506; (c) J. Li and D. Menche, Synthesis, 2009, 2293.
2 (a) Modern Aldol Reactions, ed. R. Mahrwald, Wiley-VCH,
Weinheim, 2004; (b) I. Paterson, in Asymmetric Synthesis—The
The optically active syn and anti 1,2-hydroxyalkyl moieties 5
obtained this way are versatile chiral building blocks for
natural products. The presence of a double bond13 in their
structure together with the presence of a protected primary
alcohol functionality opens a wide array of possible trans-
formations. An example of the synthetic potential of compounds
5 is shown in Scheme 4. A three-step deprotection–protection
sequence starting with compound syn-5b afforded diolefin 7a
in 80% combined yield. The latter was converted, by a ring-
closing metathesis,14 into g-ethyl substituted a,b-unsaturated
d-lactone 8a in 97% yield (Scheme 4a).
This type of g-ethyl substituted lactones is of great interest
because of its presence in a large number of natural products
that possess important biological activities including pironetin,15
phostalomycins14b,16 and bitungolides.17 This new methodo-
logy represents a catalytic alternative to the chiral boron-
mediated pentenylation14b which proceeds in the same fashion
as the chiral auxiliary-assisted asymmetric crotylation.3 As an
Essentials, ed. M. Christmann and S. Brase, Wiley-VCH,
¨
Weinheim, 2007, pp. 293–298; (c) B. M. Trost and C. S. Brindle,
Chem. Soc. Rev., 2010, 39, 1600.
3 R. W. Hoffmann, in Stereocontrolled Organic Synthesis,
ed. B. M. Trost, Blackwell Scientific Publications, Cambridge,
1994, 259–274.
4 J. A. Marshall, Chem. Rev., 2000, 100, 3163.
5 Y. Guindon, K. Houde, M. Pre
S. R. Landry, B. Daoust, M. Bencheqroun and B. Gue
J. Am. Chem. Soc., 2001, 123, 8496.
´
vost, B. Cardinal-David,
´
rin,
6 (a) S. Hanessian, J. Ma and W. Wang, J. Am. Chem. Soc., 2001,
123, 10200; (b) A. Whitehead, J. P. McParland and P. R. Hanson,
Org. Lett., 2006, 8, 5025.
´
7 (a) F. Lopez, A. W. van Zijl, A. J. Minnaard and B. L. Feringa,
Chem. Commun., 2006, 409; (b) K. Geurts, S. P. Fletcher and
B. L. Feringa, J. Am. Chem. Soc., 2006, 128, 15572.
8 For reviews on Cu-catalalyzed AAA, see: (a) S. Harutyunyan,
T. den Hartog, K. Geurts, A. J. Minnaard and B. L. Feringa,
Chem. Rev., 2008, 108, 2824; (b) A. Alexakis, J. E. Backvall,
N. Krause, O. Pamies and M. Die
2796.
¨
´
guez, Chem. Rev., 2008, 108,
9 (a) J. A. Marshall, J. D. Trometer and D. G. Cleary, Tetrahedron,
1989, 45, 391; (b) A. R. Ellwood, A. J. P. Mortimer, D. A. Tocher
and M. J. Porter, Synlett, 2008, 2199.
10 The (S)-enantiomer of allyl bromide 4 was chosen for our studies
but also the (R)-enantiomer is readily available from L-ascorbic
acid: C. Hubschwerlin, Synthesis, 1986, 962.
11 E. R. Bartholomew, S. H. Bertz, S. Cope, M. Murphy and
C. A. Ogle, J. Am. Chem. Soc., 2008, 130, 11244.
12 C. C. Tseng, S. D. Paisley and H. L. Goering, J. Org. Chem., 1986,
51, 2884.
13 For an example of versatile use of a terminal olefin, see: T. den
´
Hartog, B. Macia, A. J. Minnaard and B. L. Feringa, Adv. Synth.
Catal., 2010, 352, 999.
14 (a) A. Furstner and K. Langemann, J. Am. Chem. Soc., 1997, 119,
¨
9130; (b) S. Shibahara, M. Fujino, Y. Tashiro, K. Takahashi,
J. Ishihara and S. Hatakeyama, Org. Lett., 2008, 10, 2139.
15 S. Kobayashi, K. Tsuchiya, T. Harada, M. Nishide, T. Kurokawa,
T. Nakagawa, N. Shimada and K. Kobayashi, J. Antibiot., 1994,
47, 697.
16 S. Fushimi, S. Nishikawa, A. Shimazu and H. Seto, J. Antibiot.,
1989, 42, 1019.
17 S. Sirirath, J. Tanaka, I. I. Ohtani, T. Ichiba, R. Rachmat, K. Ueda,
T. Usui, H. Osada and T. Higa, J. Nat. Prod., 2002, 65, 1820.
Scheme 4 Reagents and conditions: (a) (i) AcOH, H2O, rt; (ii)
TBDPSCl (1.1 eq.), imidazole (1.1 eq.), DMAP (cat.), DMF, 0 1C to
rt; (iii) acryloyl chloride (1.5 eq.), iPr2EtN (2 eq.), CH2Cl2, 0 1C;
(b) Grubbs 2nd generation (5 mol%), CH2Cl2, 0.01 M, reflux, 12 h.
P = TBDPS.
c
This journal is The Royal Society of Chemistry 2011
Chem. Commun., 2011, 47, 5843–5845 5845